Clinical trial NCT02380092: Post Market Clinical Follow Up of LEGION™ Primary TKS With VERILAST™
Official title: A Multicentre, Prospective, Post Market Clinical Follow Up Study of the LEGION™ Primary Total Knee System With VERILAST™ Bearing Surface
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Degenerative Joint Disease
Keywords: Knee
Post-Market Surveillance
Legion
Verilast
Degenerative Joint Disease
Lead sponsor: Smith & Nephew, Inc.
Sponsor class: INDUSTRY
First posted: 2015-03-05
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects who are scheduled to have Total Knee Arthroplasty with the Legion Primary Total Knee System due to Degenerative Joint Disease.

Brief summary: LEGION™ Primary Total Knee System is CE-marked and marketed in all study regions. This study serves as post-market surveillance for LEGION™ Primary Total Knee System with the VERILAST™ bearing surface (OXINIUM™ femoral component with highly cross-linked polyethylene tibial insert).

All study subjects will receive a LEGION™ Primary Total Knee System with VERILAST™ bearing surface and the results will be analysed against historical data from patients who received a Genesis II knee replacement.

Detailed description: The LEGION™ Primary Total Knee System (TKS) is a comprehensive, state-of-the-art system that empowers surgeons to address diverse surgical challenges and provide personalized joint care. The LEGION™ Primary TKS implant designs were built on the legacy of the GENESIS™ II TKS. For more than 15 years and in more than 30 countries, the GENESIS™ II TKS has achieved outstanding clinical outcomes.

As CE-mark and 510k approval for the LEGION™ Primary TKS has been obtained, it is being used in clinical practice in several countries including Europe and the US but clinical studies need to be carried out in order to confirm its safety and efficacy and in order to conform to the medical device directives (MEDDEV. 2.7.1 Rev.3).

This study is therefore a post-market study to evaluate the short-, mid- and long-term safety and effectiveness of the LEGION™ Primary TKS with VERILAST™ bearing surface (the combination of an OXINIUM™ femoral component with highly cross-linked polyethylene tibial base plate inserts). The clinical outcome from a large cohort of subjects who are treated with the LEGION™ Primary TKS as part of their standard of care will be documented. The study is designed to reflect standard clinical practice as closely as possible because it allows the results of such a study to represent the true clinical outcome that would be achieved in clinical practice, up to a maximum. Only subjects who will be treated with the LEGION™ Primary TKS as part of their normally planned care will screened for participation in this study.

Eligibility criteria: Inclusion Criteria:

* Subject requires primary TKA and has elected to use the LEGION™ Primary TKS with VERILAST™.
* Subject requires primary TKA due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis).
* Subject is of legal age to consent, agrees to consent to and to follow the study visit schedule (as defined in the study protocol and informed consent form), by signing the EC approved informed consent form.
* Routine radiographic assessment is possible.
* Subject plans to be available through ten (10) years postoperative follow-up.
* Subject is 18-75 years of age at the time of surgery.

Exclusion Criteria:

* Age \> 75 years at the time of surgery.
* Subjects with immunosuppressive disorders.
* Subject has severe pronation of the ipsilateral foot or any other relevant clinical condition contributing to abnormal ambulation (including but not limited to ankle fusion, ankle arthroplasty, previous hip fracture, ipsilateral hip arthritis resulting in flexion contracture).
* Subject has undergone a previous major surgery to the study knee (including osteotomy, fracture fix, medial or lateral ligament surgery).
* Subject has active infection or sepsis (treated or untreated).
* At the time of enrollment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the Investigator:

  * Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty.
  * Contralateral primary total knee or unicondylar knee arthroplasty.
* Subject has presence of malignant tumor, metastatic, or neoplastic disease.
* Subject has conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease).
* Subject has any acute or chronic morbidity of vascular origin that, in the opinion of the Investigator, is likely to compromise successful treatment or compliance to follow-up visits.
* Subject has inadequate bone stock to support the device (severe osteopenia, family history of severe osteoporosis or osteopenia).
* Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study.
* Subject has a Body Mass Index (BMI) \>40.0.
* Subject requires revision TKA.
* Subject is expected to require bilateral TKA within 1 year following study knee replacement.
* Subject does not understand the language used in the Informed Consent Form.
* Subject is enrolled in another clinical study at the same time.

Primary outcomes:
measure: Survival
timeFrame: 10 years
Secondary outcomes:
measure: Number of revisions
timeFrame: Discharge, 3 months, 1 year, 3 years, 5 years, 7 years, 10 years
measure: Changes in mean 2011 Knee Society Score
timeFrame: Discharge, 3 months, 1 year, 3 years, 5 years, 10 years
measure: Changes in mean Euroqol 5-D score
timeFrame: Discharge, 3 months, 1 year, 3 years, 5 years, 10 years
measure: Changes in radiographic evaluation
timeFrame: Discharge, 3 months, 1 year, 3 years, 5 years, 10 years
measure: AEs
timeFrame: Operative, Discharge, 3 months, 1 year, 3 years, 5 years, 7 years, 10 years
Other outcomes:
Locations:
city: Wien
country: Austria
facility: Evangelisches Krankenhaus Wien
city: Wien
country: Austria
facility: Orthopadische Krankenhaus Gersthof
city: Langen
country: Germany
facility: AMEOS Klinikum Seepark Geestland
state: Kreis Geestland
city: Hamburg
country: Germany
facility: OrthoCentrum
city: Saarbrücken-Dudweiler
country: Germany
facility: CaritasKlinikum St. Joseph Saarbrücken-Dudweiler
city: Straubing
country: Germany
facility: KniePraxis Prof. Dr. Tibesku
city: Santiago de Compostela
country: Spain
facility: Servicio de C.O.T. Hospital Clínico Universitario de Santiago de Compostela
Study officials:
affiliation: Director of Clinical Study Management, Global Clinical Research Operations
name: Karlie Morgan
role: STUDY_DIRECTOR
References: